An EUA for Tocilizumab (Actemra) for COVID-19
July 26, 2021 (Issue: 1629)
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic...more
- FDA News Release. Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19. June 24, 2021. Available at: https://bit.ly/3AcipzX. Accessed July 8, 2021.
- NIH. Coronavirus disease 2019 (COVID-19) treatment guidelines. July 8, 2021. Available at: https://bit.ly/3w2faYJ. Accessed July 8, 2021.
- Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. June 25, 2021. Available at: https://bit.ly/3xnQqLL. Accessed July 8, 2021.
- WHO. Therapeutics and COVID-19: living guideline. v6.1. July 6, 2021. Available at: https://bit.ly/3wsYsSe. Accessed July 8, 2021.
- RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693.
- Remdesivir (Veklury) for COVID-19. Med Lett Drugs Ther 2020; 62:186.
- An EUA for baricitinib (Olumiant) for COVID-19. Med Lett Drugs Ther 2020; 62:202.
- S Khiali et al. A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J Clin Pharmacol 2020; 60:1131.
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637.
- C Salama et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384:20.
- IO Rosas et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021; 384:1503.
- FDA. Fact sheet for health care providers. Emergency Use Authorization for Actemra (tocilizumab). June 2021. Available at: https://bit.ly/360BR4Q. Accessed July 8, 2021.
- The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 2021 July 6 (epub).
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
